Long-term depot neuroleptic treatment with XXXX . I. Efficacy and side effects in a 12 month study of 42 drug monitored @entity716 @entity1 .

@entity1 @entity73234 @entity716 @entity21886
In an open, prospective 12 month study of @entity73234 (PD), 42 @entity716 @entity1 diagnosed according to DSM-III were treated with a fixed depot interval and an individual dose, guided by gas chromatographic @entity21886 plasma concentration monitoring combined with clinical evaluation. Degree of illness was rated using a social-psychiatric CGI-scale and extrapyramidal side effects were evaluated by means of a modified Simpson and Angus rating scale. After six months of treatment, a statistically significant improvement was found (p less than 0.001). During the last six months a further slight reduction in mean CGI-scores was observed. Mild to moderate extrapyramidal side effects occurred in 9 @entity1 (21%) principally during the initial phase of therapy. No other side effects or changes in blood chemistry were found during the study. Plasma concentrations of @entity21886 increased during the initial 3 months and stabilized hereafter. There were however, large intra- and inter-individual variations in the @entity21886 plasma concentration/dose ratio. In addition, it was observed that plasma concentrations of @entity21886 were significantly higher in @entity1 who had been treated with neuroleptics for more than 10 years compared to those who had been treated 5 years or less. This observation indicates gradual development of tolerance to neuroleptic treatment. This study demonstrates that PD is a safe and effective remedy for maintenance therapy in @entity716 @entity1 .
